1. Clinical & Scientific Overview
Pembrolizumab (TIP-MED-000577, Reference Code [ONC-28]) is classified under
Oncology & Antineoplastic Medicines as a Immune Checkpoint Inhibitor (Immuno-Oncology) • Humanised Anti-PD-1 (Programmed Death Receptor-1) IgG4 Immune Checkpoint Inhibitor.
Within the Indian regulatory and compendial framework, it is governed under Schedule H (Prescription Only — Specialist Oncology Supervision).
Keytruda (MSD Pharmaceuticals India)
Solution for IV Infusion: 100 mg/4 mL (25 mg/mL) vial
Oncology Specialisation & Cytotoxic Safety Protocol
Immune Checkpoint Inhibitor (Immuno-Oncology)
Antineoplastic Immunotherapy
Standard Regimen & Cycle Context: 200 mg IV over 30 minutes every 3 weeks OR 400 mg IV over 30 minutes every 6 weeks.
Signature Dose-Limiting Toxicities & Organ Monitoring: IMMUNE-MEDIATED ADVERSE REACTIONS (irAEs — can occur in any organ during therapy or months after discontinuation): Immune-mediated pneumonitis, colitis, hepatitis, endocrinopathies (hypothyroidism/hyperthyroidism, hypophysitis, adrenal insufficiency, autoimmune Type 1 diabetes with DKA), nephritis, and myocarditis.
Extravasation, Premedication & Safe Cytotoxic Handling: Unlike chemotherapy toxicities, Grade >=2 immune-mediated toxicities (pneumonitis, colitis, hepatitis) are managed by withholding Pembrolizumab and initiating systemic Corticosteroids (Prednisolone 1–2 mg/kg/day tapered slowly over >=4 weeks); check TSH, free T4, LFTs, and serum creatinine before every cycle.
3. Mechanism of Action & Pharmacodynamics
Binds PD-1 receptors on T-lymphocytes, blocking interaction with tumour-expressed ligands PD-L1 and PD-L2, thereby releasing the PD-1 braking mechanism on cytotoxic CD8+ T-cells to restore anti-tumour immune surveillance.
4. Therapeutic Indications & Evidence-Supported Uses
- PD-L1 positive / metastatic NSCLC, Melanoma, Triple-Negative Breast Cancer, Head & Neck HNSCC, Renal Cell, Cervical, Endometrial, and MSI-High / dMMR solid tumours
5. Educational Dosage Context, Formulations & Administration
Educational Dosing & Regimen Summary: Educational Oncology Regimen Context (Specialist Reference Only): 200 mg IV over 30 minutes every 3 weeks OR 400 mg IV over 30 minutes every 6 weeks.
Administration & Meal Timing: 200 mg IV over 30 minutes every 3 weeks OR 400 mg IV over 30 minutes every 6 weeks.
6. Pharmacokinetics, Metabolism & Renal/Hepatic Adjustment
Specialist oncology pharmacokinetic profile; dosing depends on Body Surface Area (BSA in m2), Calvert GFR formula, or flat targeted dosing with strict organ-function adjustments.
Hepatic enzymatic activation/inactivation or proteolytic degradation (for monoclonal antibodies); see specific polymorphism and interaction notes.
Verify serum creatinine and eGFR before every cycle; see drug-specific renal dosing and uroprotection rules.
Check total bilirubin, AST, and ALT prior to each cycle; taxanes, anthracyclines, and TKIs require strict hepatic dose modification.
7. Contraindications, Precautions & High-Risk Warnings
- Severe hypersensitivity to Pembrolizumab or formulation vehicle
- Pregnancy and lactation (potent teratogen/embryotoxic class warning unless explicitly evaluated by oncology specialist)
- Severe unrecovered bone marrow aplasia or decompensated organ failure per protocol thresholds
Key Clinical Precautions: IMMUNE-MEDIATED ADVERSE REACTIONS (irAEs — can occur in any organ during therapy or months after discontinuation): Immune-mediated pneumonitis, colitis, hepatitis, endocrinopathies (hypothyroidism/hyperthyroidism, hypophysitis, adrenal insufficiency, autoimmune Type 1 diabetes with DKA), nephritis, and myocarditis.
8. Adverse Effects Profile
- IMMUNE-MEDIATED ADVERSE REACTIONS (irAEs — can occur in any organ during therapy or months after discontinuation): Immune-mediated pneumonitis, colitis, hepatitis, endocrinopathies (hypothyroidism/hyperthyroidism, hypophysitis, adrenal insufficiency, autoimmune Type 1 diabetes with DKA), nephritis, and myocarditis.
- IMMUNE-MEDIATED ADVERSE REACTIONS (irAEs — can occur in any organ during therapy or months after discontinuation): Immune-mediated pneumonitis, colitis, hepatitis, endocrinopathies (hypothyroidism/hyperthyroidism, hypophysitis, adrenal insufficiency, autoimmune Type 1 diabetes with DKA), nephritis, and myocarditis.
9. Major Drug–Drug, Drug–Food & Drug–Herb Interactions
- IMMUNE-MEDIATED ADVERSE REACTIONS (irAEs — can occur in any organ during therapy or months after discontinuation): Immune-mediated pneumonitis, colitis, hepatitis, endocrinopathies (hypothyroidism/hyperthyroidism, hypophysitis, adrenal insufficiency, autoimmune Type 1 diabetes with DKA), nephritis, and myocarditis.
- Avoid live-attenuated vaccines during immunosuppressive chemotherapy; verify CYP3A4, UGT1A1, DPD, and QTc interactions before each cycle.
10. Clinical Monitoring, Patient Counselling & Storage
Clinical & Laboratory Monitoring: Unlike chemotherapy toxicities, Grade >=2 immune-mediated toxicities (pneumonitis, colitis, hepatitis) are managed by withholding Pembrolizumab and initiating systemic Corticosteroids (Prednisolone 1–2 mg/kg/day tapered slowly over >=4 weeks); check TSH, free T4, LFTs, and serum creatinine before every cycle.
Pharmacist Patient Counselling Points:
- Unlike chemotherapy toxicities, Grade >=2 immune-mediated toxicities (pneumonitis, colitis, hepatitis) are managed by withholding Pembrolizumab and initiating systemic Corticosteroids (Prednisolone 1–2 mg/kg/day tapered slowly over >=4 weeks); check TSH, free T4, LFTs, and serum creatinine before every cycle.
- Report fever >=38.0°C (100.4°F) immediately (medical emergency: possible febrile neutropenia).
- Follow strict reproductive contraception and safe cytotoxic oral handling instructions.
Storage, Stability & Dispensing Safeguards: Unlike chemotherapy toxicities, Grade >=2 immune-mediated toxicities (pneumonitis, colitis, hepatitis) are managed by withholding Pembrolizumab and initiating systemic Corticosteroids (Prednisolone 1–2 mg/kg/day tapered slowly over >=4 weeks); check TSH, free T4, LFTs, and serum creatinine before every cycle.
11. Visual Pharmacology & Mechanism Diagram (svg-v339-01-adme-12-step-journey)
12. Authoritative References, Regulatory Sources & Editorial Disclaimer
Primary Compendial & Guideline Reference: National Cancer Grid (NCG) India Consensus Guidelines; NLEM 2022 Antineoplastic Section; Indian Pharmacopoeia (IP) & CDSCO Approved Oncology Prescribing Information.
Official Verification Portals: National Cancer Grid (NCG) India — Evidence-Based Oncology Guidelines • CDSCO — Central Drugs Standard Control Organization Approved Drug Data • Indian Pharmacopoeia Commission (IPC)
Last Medically & Pharmaceutically Reviewed: 2026-11-10 • Verification Status: VERIFIED_EDUCATIONAL_CONTENT
Educational & Clinical Disclaimer: This reference profile is published solely for pharmacy education, academic study, and professional clinical reference. It does not substitute for patient-specific clinical judgement, qualified specialist oncology/medical supervision, or official CDSCO/IP prescribing information. Never self-medicate with prescription, Schedule H/H1/X, NDPS, or oncology medicines.